For research use only, not for therapeutic use.
CCT020312（Cat No.:I005895）is a small molecule inhibitor specifically targeting the enzyme GSK-3 (glycogen synthase kinase 3), known for its role in various cellular processes, including metabolism, cell proliferation, and apoptosis. By inhibiting GSK-3, CCT020312 can modulate signaling pathways implicated in neurodegenerative diseases and cancer, offering potential therapeutic benefits. Research has shown its ability to enhance neurogenesis and protect against neuronal damage, making it of particular interest in conditions like Alzheimer’s disease. Its selective action and ability to penetrate the blood-brain barrier position CCT020312 as a promising candidate for further drug development.
| Catalog Number | I005895 |
| CAS Number | 324759-76-4 |
| Synonyms | CCT020312; CCT-020312; CCT 020312.;6-Bromo-3-[5-(4-bromo-phenyl)-1-(3-diethylamino-propionyl)-4,5-dihydro-1H-pyrazol-3-yl]-4-phenyl-1H-quinolin-2-one |
| Molecular Formula | C31H30Br2N4O2 |
| Purity | ≥95% |
| Solubility | Soluble in DMSO |
| Storage | 0 - 4°C for short term ,or -20 °C for long term |
| IUPAC Name | 6-bromo-3-[3-(4-bromophenyl)-2-[3-(diethylamino)propanoyl]-3,4-dihydropyrazol-5-yl]-4-phenyl-1H-quinolin-2-one |
| InChI | InChI=1S/C31H30Br2N4O2/c1-3-36(4-2)17-16-28(38)37-27(20-10-12-22(32)13-11-20)19-26(35-37)30-29(21-8-6-5-7-9-21)24-18-23(33)14-15-25(24)34-31(30)39/h5-15,18,27H,3-4,16-17,19H2,1-2H3,(H,34,39) |
| InChIKey | OAXDKXMGESZLKV-UHFFFAOYSA-N |
| SMILES | CCN(CC)CCC(=O)N1C(CC(=N1)C2=C(C3=C(C=CC(=C3)Br)NC2=O)C4=CC=CC=C4)C5=CC=C(C=C5)Br |
| Reference | </br>1:Stockwell SR, Platt G, Barrie SE, Zoumpoulidou G, Te Poele RH, Aherne GW, Wilson SC, Sheldrake P, McDonald E, Venet M, Soudy C, Elustondo F, Rigoreau L, Blagg J, Workman P, Garrett MD, Mittnacht S. Mechanism-based screen for G1/S checkpoint activators identifies a selective activator of EIF2AK3/PERK signalling. PLoS One. 2012;7(1):e28568. doi: 10.1371/journal.pone.0028568. PubMed PMID: 22253692; PubMed Central PMCID: PMC3257223. |
